

Update: News Comment

2026-01-26

Bioextrax: Advancements with the candy producer

- Regulatory evaluation successfully completed
- Green light for the test panel to begin its work
- We keep the fair value at SEK 3.7 per share

Analyst	Jacob Murat 073-6006986 jacob.murat@vhcorp.se
----------------	---

Stock ticker:	BIOEX
Industry:	Biotech
Listed on:	Nasdaq First North
Latest share price (SEK):	2,39
Market cap (MSEK):	113,8
Enterprise Value (MSEK):	105,8
Total number of shares (M):	47,60
- of which free float (M):	27,34

VHCF fair value per share	
DCF model	SEK 3,7

Address:	Bioextrax AB Skifervägen 76 224 78 Lund
Webpage:	bioextrax.com
CEO:	Edvard Hall

Main owners (30 Sept 2025)	Capital (%)
Nordnet Pensionsförsäkring	8,6
Avanza Pension	6,9
Henrik Nilsson	4,8
Rajni Hatti, Kaul	4,4
Niklas Borgquist	3,5



Source: Västra Hamnen Corporate Finance

Bioextrax recently communicated that the candy producer's experts have completed their regulatory evaluation. This project has the potential to be Bioextrax largest and most profitable one. The candy producer needed to perform the final test in an external lab, which has now returned with positive results, albeit somewhat delayed. The outcome implies a green light to initiate a sensory evaluation.

The Joint Development Agreement (JDA) entails using Bioextrax biologically degradable PHO as the gum base in a new chewing gum. Currently, there are no suitable types of PHA available for this application. It is exciting that the novel material PHO has passed the regulatory evaluation and can now actually be used to produce chewing gum for consumer panel testing.

As stated in the recent press release, the current phase of the project includes three main activities, of which the first two have now been completed:

- Evaluation of the material properties of Bioextrax PHO
- Regulatory evaluation, and
- Sensory evaluation conducted by a test panel.

The last remaining step of the phase is approval from the test panel. CEO **Edvard Hall** stated in the [latest report presentation](#) that this is the activity in the current phase with the highest degree of risk. It is noteworthy that a negative response from the test panel would likely lead to tweaks in the formula, which, of course, would lead to further delays.

Given a positive response from the test panel, the next phase would be a pilot production phase, in which Bioextrax will deliver PHA for prototype development. When such a phase will be initiated remains to be seen.

Although delayed, the recent news is a step in the right direction. Our fair value hinges on high growth in the coming years, and a successful project with the candy producer could generate substantial revenue for Bioextrax.

We will await the year-end report on February 19 before adjusting our model, and we keep our fair value unchanged at SEK 3.7 per share.

Disclaimer

This marketing material has been prepared by Västra Hamnen Corporate Finance AB ("Västra Hamnen").

The material has not been prepared in accordance with the regulations designed to promote the independence of investment research and it is not subject to any legal prohibition on dealing ahead of the dissemination of the report.

The material has been prepared based on publicly available information that Västra Hamnen has deemed to be reliable. However, it cannot be guaranteed that the information is correct. The material is published for marketing purposes and does not purport to constitute a basis for any investment decision. The information provided herein does not constitute investment advice and neither does the information take into consideration the individual needs, goals and circumstances of any particular recipient of this material. The reader is recommended to seek supplementary information elsewhere and to obtain relevant and specific professional advice before making any investment decision.

All views, opinions and conclusions communicated through this material shall be seen as valid on the publication date of this report only and are subject to change without notice. None of the information herein shall be construed as a recommendation or solicitation for the purchase or sale of any financial instrument.

In no event will Västra Hamnen be liable for direct, indirect or incidental damages resulting from the information in this report. Financial instruments can decrease as well as increase in value. Past performance is not indicative of future results.

The material is not directed at any such person, physical or legal, to whom the distribution of such material would imply a risk of violation of any laws or regulations applicable in Sweden or any other jurisdiction.

Contents of this report shall not be copied, reproduced or distributed to any third party without prior written permission from Västra Hamnen.

Conflicts of interest

Recipients should note that this material has been commissioned by the company mentioned in this report and that Västra Hamnen has received remuneration from the company for the production of the report. The remuneration is fixed and predetermined and in no way dependent on the content of the report or the views expressed herein.

The company mentioned in the report has reviewed the material prior to publication. The recipient may assume that this review has led to changes in the factual information presented in the report. Any assumptions, conclusions and scenarios are however the result of Västra Hamnen's analysis of available information.

Västra Hamnen has internal rules prohibiting all of its employees from buying or selling shares issued by companies with which Västra Hamnen has ongoing agreements to produce marketing material like the present.

Västra Hamnen has a separate agreement with Bioextrax to act as its Certified Adviser on Nasdaq First North Growth Market Stockholm.

Västra Hamnen Corporate Finance AB

Stortorget 13 A

211 22 Malmö

Telefon: +46 40 200 250

E-post: info@vhcorp.se

